Simplex Trading’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$510K Buy
+18,200
New +$597K ﹤0.01% 3241
2025
Q4
Sell
-26,500
Closed -$730K 9188
2025
Q3
$730K Buy
26,500
+24,700
+1,372% +$851K ﹤0.01% 3372
2025
Q2
$56K Sell
1,800
-2,300
-56% -$74K ﹤0.01% 5812
2025
Q1
$136K Sell
4,100
-600
-13% -$21.5K ﹤0.01% 4733
2024
Q4
$161K Buy
4,700
+3,000
+176% +$103K ﹤0.01% 4724
2024
Q3
$68K Buy
1,700
+1,300
+325% +$45.7K ﹤0.01% 5600
2024
Q2
$12K Sell
400
-8,900
-96% -$268K ﹤0.01% 7291
2024
Q1
$312K Sell
9,300
-1,900
-17% -$61K ﹤0.01% 4341
2023
Q4
$361K Buy
11,200
+6,200
+124% +$173K ﹤0.01% 4035
2023
Q3
$163K Buy
5,000
+3,200
+178% +$111K ﹤0.01% 4571
2023
Q2
$63K Sell
1,800
-8,700
-83% -$300K ﹤0.01% 5591
2023
Q1
$342K Buy
10,500
+10,100
+2,525% +$460K ﹤0.01% 3675
2022
Q4
$22K Sell
400
-14,300
-97% -$786K ﹤0.01% 6778
2022
Q3
$651K Buy
14,700
+3,000
+26% +$146K ﹤0.01% 3156
2022
Q2
$570K Buy
+11,700
New +$527K ﹤0.01% 3283
2021
Q1
Sell
-44
Closed -$159K 9301
2020
Q4
$159K Buy
+44
New +$1.78K ﹤0.01% 4905

Other funds holding HRMY

Simplex Trading's HRMY Position: Q4 2025 in Review

Simplex Trading sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 6,003 shares — an estimated $165K sold.

Simplex Trading first reported a position in HRMY in Q1 2022 and held it in 7 quarters. The position peaked at $168K in Q2 2024. 323 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • Simplex Trading reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 6,003 Harmony Biosciences shares in Q4 2025, an estimated $165K.
  • Simplex Trading first reported a position in Harmony Biosciences in Q1 2022 and held it in 7 quarters.
  • Simplex Trading's Harmony Biosciences position peaked at $168K in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.